What is Beam Therapeutics's D&A?

Beam Therapeutics (BEAM) reported D&A of $5.61M in Q1 2026.

How has Beam Therapeutics's D&A changed year-over-year?

Beam Therapeutics's D&A increased by 1.4% year-over-year, from $5.53M to $5.61M.

What is the long-term trend for Beam Therapeutics's D&A?

Over 4 years (2021 to 2025), Beam Therapeutics's D&A has grown at a 31.5% compound annual growth rate (CAGR), from $7.45M to $22.29M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Beam Therapeutics BEAM D&A

D&A at other companies

Vertex PharmaceuticalsVRTX

$55.9M+15.5%

Arrowhead ResearchARWR

$6.37M+4.7%

CRISPR TherapeuticsCRSP

$4.32M-8.8%

Cogent Biosciences, Inc.COGT

$626K-2.2%

PTC TherapeuticsPTCT

$15.41M+113%

BridgeBio PharmaBBIO

$1.19M-7.6%

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.51B+24.5%

Enterprise value$3.47B+51.2%

P/S21.4×-23.0×

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's D&A?: Beam Therapeutics (BEAM) reported D&A of $5.61M in Q1 2026.
How has Beam Therapeutics's D&A changed year-over-year?: Beam Therapeutics's D&A increased by 1.4% year-over-year, from $5.53M to $5.61M.
What is the long-term trend for Beam Therapeutics's D&A?: Over 4 years (2021 to 2025), Beam Therapeutics's D&A has grown at a 31.5% compound annual growth rate (CAGR), from $7.45M to $22.29M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.